Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · May 01, 2022

Treatment Response and 5-Year Survival Outcome in Breast Cancer Patients After the Use of MammaPrint and BluePrint to Guide Preoperative Systemic Therapy

European Journal of Cancer


Additional Info

European Journal of Cancer
Treatment response and 5-year distant metastasis-free survival outcome in breast cancer patients after the use of MammaPrint and BluePrint to guide preoperative systemic treatment decisions
Eur. J. Cancer 2022 May 01;167(xx)92-102, E Göker, MP Hendriks, M van Tilburg, A Barcaru, L Mittempergher, A van Egmond, M Kleijn, D Generali

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading